Amylyx Pharmaceuticals Inc · Q1 2025 earnings

Briefing

Amylyx Pharmaceuticals reported financial results for the first quarter ended March 31, 2025.

Amylyx Pharmaceuticals reported a net loss of $35.9 million for the first quarter of 2025, a significant improvement compared to the $118.8 million net loss in the same period last year. The company's cash position strengthened to $204.1 million, extending its expected cash runway through the end of 2026. The quarter saw continued progress in clinical trials, particularly the pivotal Phase 3 LUCIDITY trial for avexitide in PBH and the initiation of the Phase 1 LUMINA trial for AMX0114 in ALS.

• Net loss improved significantly to $35.9 million in Q1 2025 from $118.8 million in Q1 2024, primarily due to the discontinuation of RELYVRIO/ALBRIOZA sales and associated costs.
• Cash, cash equivalents, and marketable securities increased to $204.1 million as of March 31, 2025, supported by a public offering, extending the cash runway through the end of 2026.
• Progress was made in the pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia (PBH), with enrollment completion expected in 2025.
• The company initiated the Phase 1 LUMINA trial of AMX0114 for ALS and anticipates early cohort data in 2025.

Headline financials

Revenue & EPS history

Amylyx expects to complete enrollment for the LUCIDITY trial of avexitide in PBH in 2025, with topline data in the first half of 2026 and potential commercial launch in 2027. They also anticipate early cohort data from the LUMINA trial of AMX0114 in ALS in 2025 and unblinded analysis from the ORION trial of AMX0035 in PSP in Q3 2025. The company's cash runway is expected to last through the end of 2026.